Developing a Solution
For people with diabetes who use insulin, we know how difficult it is to maintain blood glucose levels within a certain range. So too, is predicting when low blood sugar can happen. In the case of severe hypoglycemia, it can lead to serious medical complications, including seizures, coma, and even a risk of death.
People experiencing a severe hypoglycemic episode cannot self-administer the lifesaving medication they need: glucagon, a hormone that causes the liver to release glucose into circulation. Instead, they are left to depend on a broad safety net of family, friends, coworkers, schoolteachers, and even bystanders to act in an emergency by rescuing them with glucagon.
It is essential that people with diabetes who use insulin and those that surround them are prepared, confident, and empowered to take action in the event of severe hypoglycemia.
We are working diligently to place our novel glucagon rescue treatment in the hands of people who use insulin and those who touch their lives. Study results have been positive to date. Data from our phase 3 clinical trials have started to be presented at conferences around the world.
Follow these links to see reporters' and bloggers' coverage of Locemia and its glucagon nasal powder (GNP).
Video interview with Dr. J.F. Yale presenting results at EASD 2015 Annual Meeting of Locemia’s human factors study which compared the usability of GNP vs. injectable glucagon in simulated severe hypoglycemia rescue
Short article summarizing Locemia’s glucagon nasal powder (GNP) data presented at the EASD 2015 Annual Meeting
Piece about the pediatric study assessing the safety and efficacy of glucagon nasal powder (GNP) as presented by Dr. J.L. Sherr
Clinical Endocrinology News / Diabetes Hub / PM 360 / Emergency Medicine
Article on the pediatric efficacy and safety data presented at the 2015 European Association for the Study of Diabetes (EASD) Annual Meeting
Article covering GNP pediatric study and study which compared the ability of caregivers and acquaintances to administer GNP and injectable glucagon in a simulated severe hypoglycemia emergency
Medscape (sign up for free to read article)
A piece featuring lead author Dr. J.L. Sherr’s presentation at the 2015 EASD Annual Meeting of GNP phase III clinical pediatric trial
Endocrine Today / Healio.com
Blog on glucagon and GNP’s potential impact to “the face of severe hypoglycemia”
Interview with Locemia’s CEO Claude Piché and Dr. J.L. Sherr on GNP pediatric clinical study
Article on severe hypoglycemia in children and GNP pediatric clinical study results presented at the ADA
Video interview with Dr. J.L. Sherr, on the clinical study evaluating the efficacy and safety of GNP in the pediatric population compared with injectable glucagon; ADA 2015
Interview with Dr. J.L. Sherr, lead author, about GNP pediatric efficacy and safety study
Locemia’s Chairman Robert Oringer and CEO Claude Piché describe the company’s inspiration and progress
Article on T1D Exchange release of needle-free glucagon trial results
Interview with Locemia’s co-creators Robert Oringer and Claude Piché following Phase III data release at ATTD Conference
Post on the T1D Exchange findings on severe hypoglycemia research and nasal glucagon trials
Every Day Ups and Downs Blog
CEO Claude Piché presents at Partnering for Cures 2014 (starts at 08:30)
FasterCures - YouTube